Teva, Boehringer Slapped With New Pay-For-Delay Suit

Law360, Los Angeles (January 24, 2014, 6:03 PM EST) -- Teva Pharmaceuticals Inc. and Boehringer Ingelheim Pharmaceuticals Inc. were slapped on Friday with another proposed class action, this one in Pennsylvania federal court, over an alleged $120 million deal to delay the entry into the market of a generic version of a stroke-prevention medication.

A health and welfare fund for the National Electrical Contractors Association and the International Brotherhood of Electrical Workers claimed in a class action complaint that a pay-for-delay agreement between Boehringer and Teva subsidiary Barr Pharmaceuticals Inc. has caused indirect purchasers of Boehringer's...
To view the full article, register now.